Journals / KONURALP TIP DERGİSİ / 2026 / Volume: 9 Issue: 3

Evaluation of Patients with Cutaneous Leishmaniasis Who Admitted to Dermatology Clinic in Kahramanmaras Sutcu Imam Univercity Medical Faculty

Kahramanmaraş Sütçü İmam Üniversitesi Dermatoloji Kliniğinde Kutanöz Leişmanya Tanısı ile Kabul Edilen Hastaların Değerlendirilmesi

Serpil Şener(INONU UNIV)
Ülkü Karaman(Ordu Ünitversitesi)
Gülden Hakverdi(INONU UNIV)
Gülbahar Saraç(INONU UNIV)
Burcu Kayhan Tetik(INONU UNIV)
Pages
—
Publication Date
2017-09-22
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Intralesional meglumine antimoniate was applied for patients treatment

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Leishmaniasis is a group of diseases, in different clinical forms, caused by the intracellular protozoan parasites, Leishmania species.
📊
Key Findings & Data:The aim of this study is to examine the status of Cutaneous Leismaniasis(CL) in the Kahramanmaras province and contribute to the prevention of the disease in this region. 20 CL cases were reported officially in 2009.
💡
Conclusion & Impact:Intralesional meglumine antimoniate was applied for patients treatment
🔬Design:Research Article
📍Scope:2009 Verileri
⚙️Variables:Cutaneous Leismaniasis · Kahramanmaras · meglumine antimoniate

Abstract

Leishmaniasis is a group of diseases, in different clinical forms, caused by the intracellular protozoan parasites, Leishmania species. The disease is transmitted by a female sand fly infected with the parasite sucking blood from people. Leishmania spp. causes three main clinical forms: cutaneous, mucocutaneous, and visceral disease. The clinical forms may vary by species and/or region of acquisition. Two forms are observed in Turkey; visceral leishmaniasis and cutaneous leishmaniasis. The aim of this study is to examine the status of Cutaneous Leismaniasis(CL) in the Kahramanmaras province and contribute to the prevention of the disease in this region. 20 CL cases were reported officially in 2009. Out of 20 cases, 12 and 8 were female and male. According to smear and biopsy, was found positive in 13 cases, and negative in 7 cases and the results of biyopsy was assessment as CL. Intralesional meglumine antimoniate was applied for patients treatment

Özet

Leişmanya hücre içi protozoan parazitlerden kaynaklanan, farklı klinik formlardaki bir hastalık grubudur. Hastalık, parazitle enfekte olmuş dişi tatarcık sineğinin insandan kan emerken insana geçmesi ile meydana gelir. Leişmanya türleri Kutanöz, Mukokutanöz ve visseral formlar olmak üzere 3 esas klinik formu vardır. Klinik formlar türe ve/veya hastalığın alındığı bölgeye göre değişiklik gösterir. Türkiye’de visseral ve kutanöz leişmanya formları gözlenir. Bu çalışmanın amacı, Kahramanmaraş ilinde Kutanöz Leişmanya (KL) durumun incelemek ve bu bölgede hastalığın önlenmesine katkı sağlamaktır. 2009 yılında 20 KL vakası resmi olarak bildirilmiştir. 20 vakanın 12’ si bayan 8’i erkek idi. Sürüntü ve biyopsi sonuçlarına göre 13 vaka pozitif bulundu, biyopsi sonucuna göre 7 vaka KL negatif olarak değerlendirildi. Hastaların tedavilerinde intralezyonal meglumum antimonu uygulandı.

🔖

Cite This Article

Şener, S., Karaman, Ü., Hakverdi, G., Saraç, G., Tetik, B. K. (2017). Evaluation of Patients with Cutaneous Leishmaniasis Who Admitted to Dermatology Clinic in Kahramanmaras Sutcu Imam Univercity Medical Faculty. KONURALP TIP DERGİSİ, Volume: 9 Issue: 3. https://doi.org/10.18521/ktd.288157

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Atasoy A, Pasa S, Ozensoy Toz S, et al. Seroprevalance of canine visceral Leishmaniasis around the Aegean cost of Turkey. Kafkas Univ Vet Fak Derg 2010; 16 (1): 1-6.
  2. WHO Technical Report Series, 949. Control of the Leishmaniasis report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22-26 March 2010.
  3. Memişoğlu HR. Kutanöz Leishmaniasis. Ankem Derg 1997; 11 (No.3): 319-2.
  4. WHO. Expert Committee. Control of the Leishmaniasis. Geneva, 1990.
  5. WHO. The Leishmaniasis. Control of Tropical Diseases, Geneva, 1993.
  6. Dos Santos AO: Ueda-Nakamura T, DiasFilho BP, et al. Copaiba Oil: An Alternative to Development of New Drugs against Leishmaniasis. Evid Based Complement Alternat Med. 2012; 2012: 898419.
  7. Doğan N, Bör O, Dinleyici EC, et al. Investigation of anti-Leishmania seroprevalence by different serologic assays in children inhabiting in then or the westernpart of Turkey. Mikrobiyol Bul 2008; 42 (1): 103-11.
  8. Corral MJ, González E, Cuquerella M, et al. Improvement of 96-well microplate assay for estimation of cell grow than dinhibition of Leishmania with Alamar Blue. J Microbiol Methods 2013; 94 (2): 111-6.
  9. TC. Sağlık Bakanlığı Sağlık Araştırmaları Genel Müdürlüğü Sağlık İstatistikleri Yıllığı 2014 verileri, Ankara, 2015.
  10. Bulaşıcı Hastalıkların Laboratuvar Tanısı için Saha Rehber (Parazitoloji / Mikrobiyolojik Tanımlama / P-MT-05 / Sürüm: 1.1 / 01.01.2015) (Erişim Tarihi: 05.12.2016)
  11. de Araújo MV, de Souza PS, de Queiroz AC, et al. Synthesis, leishmanicidal activity and theoretical evaluations of a series of substituted bis-2-hydroxy-1,4-naphthoquinones. Molecules 2014;19 (9): 15180-95.
  12. Barbosa TP, Sousa SC, Amorim FM, et al. Design, synthesis and antileishmanial in vitroactivity of newseries of chalcones-likecompounds: A molecular hybridization approach. Bioorg Med Chem 2011; 19 (14): 4250-6.
  13. Khalid FA, Nazar M. Abdalla, Husam Eldin O. Et al. Treatment of Cutaneous leishmaniasis with some Local Sudanese Plants (Neem, Garad&Garlic) Turkiye Parazitol Derg 2004; 28 (3): 129-32.
  14. Bekhit AA, Haimanot T, Hymete A Evaluation of some 1H-pyrazole derivatives as a
  15. dual acting antimalarial and anti-leishmanial agents. Pak J Pharm Sci 2014; 27 (6):